Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth - Test2 - elhamkhani - TriplyDB

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

http://www.wikidata.org/entity/Q34221890

about

Transition Metal Intercalators as Anticancer Agents-Recent Advances Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds Mycobacterium tuberculosis Thioredoxin Reductase Is Essential for Thiol Redox Homeostasis but Plays a Minor Role in Antioxidant Defense Deubiquitinases (DUBs) and DUB inhibitors: a patent review Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.Overexpression of ubiquitin specific peptidase 14 predicts unfavorable prognosis in esophageal squamous cell carcinoma.Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.Deubiquitinases in cancer.Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy.Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer.Chemical biology of anticancer gold(III) and gold(I) complexes.Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.Regulation of pluripotency and differentiation by deubiquitinating enzymes.A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges.Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication.Ubiquitin-specific protease 14 regulates LPS-induced inflammation by increasing ERK1/2 phosphorylation and NF-κB activation.Bilirubin neurotoxicity is associated with proteasome inhibition.Auranofin: repurposing an old drug for a golden new age.A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers.A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death.Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.Selection and characterization of a human ovarian cancer cell line resistant to auranofin.Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination.Developing a genetic signature to predict drug response in ovarian cancer.In vitro antineoplastic effects of auranofin in canine lymphoma cells.

P2860

Q28077365-67D90CDA-CF77-4872-9C18-29A5919FADD0 Q28082497-3B2E1301-CA61-44B5-A357-93B450299457 Q28552573-8E8BFD14-295F-410A-AEFC-FC2BE78F1124 Q28834608-8C8E3FE7-6AAE-425F-ADCE-4195515E7A3E Q30646859-7307E777-1958-4A0B-9EC3-D13A6FA41533 Q33801982-5F1D7F35-7185-4A15-A5F6-DDE6ACC221EB Q33829292-F1FAB7B1-2232-40E0-9FA9-ADDEFE233313 Q33863380-E1AEBACF-FC3A-43B9-AD10-0EDED0A601D5 Q34619261-9F85B35F-50CA-4FA5-B33E-3833DB943F76 Q35615675-86B8D2BB-8DCE-4480-A89B-D6B30500B124 Q35741522-6FB202E2-6425-4534-8904-B480987D35F7 Q35955141-F893C522-1217-4C3F-B26A-22D7DD9CD11C Q36771950-2565F6C6-4A3E-4993-9850-C6C6B816C5B1 Q36772192-F8BAED0B-4A46-4002-8E5F-8E7CF80F154C Q36970245-2C38C51A-CC81-40FC-B91B-9A25D2CEEFBA Q37619364-C352E97F-0948-4E9E-BA2A-C5B6013ED11B Q37685099-E20BE0D6-E776-44E5-89E2-4381F202022C Q37706134-BD2A56FD-A0DE-4C81-A336-B00E2303BDC0 Q37706728-155F1A0F-01A6-4311-8BB9-50F5F4015A02 Q37745339-66FC4A15-B29E-40F4-B353-F3B9D2D1C0D9 Q38418786-ED233075-1816-469E-9D9E-B8B5D679147D Q38755076-A64BD2CB-32D3-48ED-9A86-081DEB479712 Q38777221-4B6C4F52-250A-48B0-8452-3BA032C992B3 Q38855269-2DBB022C-BBB5-47D4-ADF8-140EE050D542 Q38882024-D64401AA-4A38-4FD5-85A3-0E8BE08E3EAA Q38989377-C9CF1505-102A-4268-9214-69AEF76B184C Q39171781-C675DC93-F51C-405B-983C-0CA9A7A905A8 Q40269812-E7E762A4-AE57-451F-9779-4DF45C09B834 Q41084319-D53BED3E-CE6E-4003-BD56-53ADCF50239D Q41474201-22E44A05-4DCC-40C5-A3E6-8ED9A3A50B71 Q42362660-1E95AF6A-3285-477C-AB94-F7EA541DFDDD Q43226621-5FD8A24C-C5A2-4F3A-BF37-FD2D1C21BED1 Q46294171-14EE999E-37A4-4901-8F07-A0FA7E68B25D Q47098444-02E11E6D-133B-42AB-9410-786E259164EE Q47135396-E9EB5BCD-55B1-47E4-B530-73A15783044A Q47446573-3719ECE4-A813-4FCF-B11A-682D902E5DE0 Q47631097-884C315E-6CD7-4894-9AA5-5FC79C0AFF76 Q48529877-CA8C110D-5921-4CBA-9556-C17D9EF69424 Q55028564-5DAC06FB-67EF-45E0-816F-9AFB34BCDCAF Q55429885-186F975B-E6AF-4759-BE13-9638EAC13159

P2860

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

http://www.wikidata.org/entity/Q34221890

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinically used antirheumatic ...... itor and inhibits tumor growth

@ast

Clinically used antirheumatic ...... itor and inhibits tumor growth

@en

Clinically used antirheumatic ...... itor and inhibits tumor growth

@nl

type

label

Clinically used antirheumatic ...... itor and inhibits tumor growth

@ast

Clinically used antirheumatic ...... itor and inhibits tumor growth

@en

Clinically used antirheumatic ...... itor and inhibits tumor growth

@nl

prefLabel

Clinically used antirheumatic ...... itor and inhibits tumor growth

@ast

Clinically used antirheumatic ...... itor and inhibits tumor growth

@en

Clinically used antirheumatic ...... itor and inhibits tumor growth

@nl

P1433

Q34221890-3016795B-2D6B-430D-877B-E27C7BE7EE1B

P1476

Q34221890-23026A30-0EC7-44DF-B4F5-628FD2B88780

P2093

Q34221890-045DA188-F25B-495F-9E90-CFA83AB39450

Q34221890-09C3CF2E-86ED-486F-A37D-1A76A8CEA736

Q34221890-0F3E6ED8-25A3-4E3F-B74F-7F63E60924FD

Q34221890-311CEB16-DB2D-411C-BD66-C7F545FF1B90

Q34221890-320A7B46-1E60-4CE2-B683-39C035EA32E6

Q34221890-3244472C-8BD1-4380-A2CC-65875F8879B5

Q34221890-431ED1A6-1A25-4DA3-8F75-B7B8209608FE

Q34221890-4F9239A6-5A91-4736-A068-02F355138E6E

Q34221890-4FAB70DC-21B3-4A9E-87C6-4880DBC1A5DA

Q34221890-569D5993-602B-4F7F-BD09-75EF0D590EDB

P2860

Q34221890-0234978A-F3F9-46F7-8331-C142517A9E38

Q34221890-0C73C26C-6C39-4420-9D6E-87F061FCE6EB

Q34221890-0DE083BA-582E-406B-B16D-6D015930DCA6

Q34221890-1075F8D3-B285-4DD5-8B6F-13F0C687F361

Q34221890-17143991-69AA-4344-AFF2-DE1A8A3832AA

Q34221890-17FFF456-9296-4696-ABFE-B43148700C59

Q34221890-2139397D-C0FF-4E5B-9EBA-E46F1382BAB6

Q34221890-259411D7-DAED-421B-B4A0-4DDB71461B54

Q34221890-285C8B0A-BF5A-43B7-B3E3-A1CF062A0813

Q34221890-2AE6E2BB-A904-4FAF-8D08-6836E3CE51EE

P304

Q34221890-D37AD9EA-82CA-496B-883B-9A4B33C166FC

P31

Q34221890-93A65B71-AA5F-41AB-B901-00C47E6B264A

P356

Q34221890-19DB7051-7FD7-4463-85DB-E677ED407A59

P407

Q34221890-2BE3ADA4-4DCC-4DBF-8AEA-D6ED3DCB1754

P433

Q34221890-20CDBB9A-50E6-4D43-88CC-6C453593E689

P478

Q34221890-009D8C85-02D7-4277-A018-2D869B82DCA0

P577

Q34221890-04A10A83-1FED-48FC-8BAA-309109B44F10

P5875

Q34221890-98E94AD8-544B-4592-9681-EDC65C4361DA

P698

Q34221890-DA78F829-665C-4F48-AB58-758A0652D796

P932

Q34221890-DA4F5D26-D60F-4951-86EC-921156627F73

P356

ONCOTARGET.2113

P1433

P1476

Clinically used antirheumatic ...... itor and inhibits tumor growth

@en

P2093

Canguo Zhao

http://www.w3.org/2001/XMLSchema#string

Changshan Yang

http://www.w3.org/2001/XMLSchema#string

Chong Zhao

http://www.w3.org/2001/XMLSchema#string

Hongbiao Huang

http://www.w3.org/2001/XMLSchema#string

Jinbao Liu

http://www.w3.org/2001/XMLSchema#string

Li Xu

http://www.w3.org/2001/XMLSchema#string

Lili Jiang

http://www.w3.org/2001/XMLSchema#string

Ningning Liu

http://www.w3.org/2001/XMLSchema#string

Ping Q Dou

http://www.w3.org/2001/XMLSchema#string

Ping Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Deubiquitylating enzymes and disease

Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome

Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53

Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14

Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes?

MEROPS: the database of proteolytic enzymes, their substrates and inhibitors

Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation

Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes

Use of RNA interference and complementation to study the function of the Drosophila and human 26S proteasome subunit S13

Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains

P304

5453-5471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2113

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263517459

http://www.w3.org/2001/XMLSchema#string

P698

24977961

http://www.w3.org/2001/XMLSchema#string

P932

4170648

http://www.w3.org/2001/XMLSchema#string